Teva Pharmaceutical Industries Ltd (TEVA): Today's Featured Drugs Laggard

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Teva Pharmaceutical Industries ( TEVA) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 1%. By the end of trading, Teva Pharmaceutical Industries fell 43 cents (-1%) to $40.79 on average volume. Throughout the day, three million shares of Teva Pharmaceutical Industries exchanged hands as compared to its average daily volume of 2.9 million shares. The stock ranged in price between $40.75-$41.40 after having opened the day at $41.31 as compared to the previous trading day's close of $41.22. Other companies within the Drugs industry that declined today were: AEterna Zentaris ( AEZS), down 15.7%, Senesco Technologies ( SNT), down 8.5%, Rigel Pharmaceuticals ( RIGL), down 8.2%, and Zalicus ( ZLCS), down 7.4%.
  • ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.

Teva Pharmaceutical Industries Limited develops, manufactures, and sells pharmaceutical products worldwide. Teva Pharmaceutical Industries has a market cap of $35.67 billion and is part of the health care sector. The company has a P/E ratio of 11.1, below the average drugs industry P/E ratio of 11.5 and below the S&P 500 P/E ratio of 17.7. Shares are up 1.8% year to date as of the close of trading on Tuesday. Currently there are 17 analysts that rate Teva Pharmaceutical Industries a buy, no analysts rate it a sell, and 10 rate it a hold.

TheStreet Ratings rates Teva Pharmaceutical Industries as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, attractive valuation levels and expanding profit margins. However, as a counter to these strengths, we find that we feel that the company's cash flow from its operations has been weak overall.

On the positive front, Sarepta Therapeutics ( SRPT), up 199.7%, Bioline Rx ( BLRX), up 16.9%, Oxygen Biotherapeutics ( OXBT), up 16.4%, and Accelr8 Technology Corporation ( AXK), up 14.9%, were all gainers within the drugs industry with Biogen Idec ( BIIB) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

FREE from Real Money's Jim Cramer: Winners and Losers Election 2012 - Steps to take NOW so you can profit no matter who is in charge! Free download now.

null

More from Markets

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%